Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Crazy About IDEXX Laboratories, Inc. (IDXX)

Page 1 of 2

Is it smart to be bullish on IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

In the 21st century investor’s toolkit, there are dozens of indicators market participants can use to watch the equity markets. Some of the most useful are hedge fund and insider trading interest. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the top hedge fund managers can outclass the broader indices by a solid amount (see just how much).

IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Equally as necessary, positive insider trading sentiment is a second way to analyze the world of equities. There are plenty of stimuli for an executive to downsize shares of his or her company, but only one, very simple reason why they would behave bullishly. Plenty of empirical studies have demonstrated the impressive potential of this method if “monkeys” understand where to look (learn more here).

Furthermore, we’re going to analyze the recent info about IDEXX Laboratories, Inc. (NASDAQ:IDXX).

How have hedgies been trading IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

Heading into Q3, a total of 14 of the hedge funds we track were bullish in this stock, a change of 27% from one quarter earlier. With the smart money’s capital changing hands, there exists a few notable hedge fund managers who were boosting their stakes meaningfully.

When using filings from the hedgies we track, Chuck Royce’s Royce & Associates had the largest position in IDEXX Laboratories, Inc. (NASDAQ:IDXX), worth close to $146.8 million, comprising 0.5% of its total 13F portfolio. Coming in second is Renaissance Technologies, managed by Jim Simons, which held a $30.7 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Remaining peers that hold long positions include Bill Miller’s Legg Mason Capital Management, Ken Griffin’s Citadel Investment Group and Jacob Gottlieb’s Visium Asset Management.

As aggregate interest spiked, specific money managers have been driving this bullishness. Royce & Associates, managed by Chuck Royce, established the largest position in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Royce & Associates had 146.8 million invested in the company at the end of the quarter. Jim Simons’s Renaissance Technologies also made a $30.7 million investment in the stock during the quarter. The following funds were also among the new IDXX investors: Bill Miller’s Legg Mason Capital Management, Ken Griffin’s Citadel Investment Group, and Jacob Gottlieb’s Visium Asset Management.

How have insiders been trading IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

Insider buying made by high-level executives is best served when the company in focus has seen transactions within the past six months. Over the last half-year time period, IDEXX Laboratories, Inc. (NASDAQ:IDXX) has experienced zero unique insiders buying, and zero insider sales (see the details of insider trades here).

We’ll check out the relationship between both of these indicators in other stocks similar to IDEXX Laboratories, Inc. (NASDAQ:IDXX). These stocks are Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Quidel Corporation (NASDAQ:QDEL), Meridian Bioscience, Inc. (NASDAQ:VIVO), Abaxis Inc (NASDAQ:ABAX), and Neogen Corporation (NASDAQ:NEOG). This group of stocks are in the diagnostic substances industry and their market caps match IDXX’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!